A FTSE 100 dividend growth stock I’d buy today and one top performer I’d consider selling

Why I’d recycle my profits from this small-cap into this evergreen FTSE 100 (INDEXFTSE: UKX) big-cap.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Investors have enjoyed a terrific ride since antibody supplier Bioventix (LSE: BVXP) arrived on the FTSE AIM market in April 2014. I first wrote about the firm that October when the share price was 680p, the forward price-to-earnings (P/E) ratio was 16, and the forward dividend yield was 3.9%. Back then, I thought the valuation looked modest “for such a fast-growing business.”

Strong performance

Fast-forward four years to today and the valuation no longer looks modest. The current share price of around 3,000p puts the forward P/E ratio at 30 and the forward dividend yield at 2.4%. I think this outcome is a good example of how a valuation re-rating can really turbocharge investor returns when a good growth story becomes accepted by the investing community.

Of course, Bioventix has earned its re-rating. Over four years, revenue is up over 125%, earnings are more than 200% higher, and the normal dividend is almost 100% higher. Throughout the period, the firm’s quality indicators have been mind-bogglingly good, and the whole set-up screams ‘special’, so I can see why many investors have clung tightly to their shares. However, there’s no denying that the now-racy valuation raises the stakes.

Should you invest £1,000 in Qinetiq Group Plc right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Qinetiq Group Plc made the list?

See the 6 stocks

Meanwhile, Bioventix keeps pumping out good figures. Today’s full-year results reveal revenue up almost 21% compared to the equivalent period last year, and pre-tax profit lifting 19%.

The firm’s debt-free balance sheet is a joy to behold and the cash pile rose by £0.8m to £7m. The money is more than the directors need to finance further growth, so they declared a special dividend of 55p per share, to be paid on top of a second interim dividend of 36p, itself up 16% on last year.

The company remains a quality outfit but forward earnings growth expectations are now the item that’s ‘modest”, cooling from the robust double-digit advances we’ve been seeing from the firm. If I still held shares in Bioventix I’d cash in my chips now to nail down my gains because I think the shares could drift lower as operational progress catches up with the valuation.

A decent long-term bet?

Instead of Bioventix, I’m tempted by FTSE 100 medical technology company Smith & Nephew (LSE: SN), which supplies joint replacements for knees, hips and shoulders; tools for minimally invasive surgery; advanced wound dressings; plus nuts, bolts, plates and other items for trauma surgery – all good stuff with apparent evergreen demand in today’s world.

The firm’s progress with revenue, profits and cash flow has been steady, albeit unspectacular, over the past few, which reflects in a keener valuation than we are seeing with Bioventix. At today’s share price close to 1,340p, the forward P/E ratio for 2019 sits at just over 17, and the forward dividend yield is a little over 2.1%. For that price, I see Smith & Nephew as equally exposed to the benefits of potential upside surprises as it is to downside risks, which is a fair proposition. I’d be happy to tuck some of the shares away for the long term.  

5 stocks for trying to build wealth after 50

The cost of living crisis shows no signs of slowing… the conflict in the Middle East and Ukraine shows no sign of resolution, while the global economy could be teetering on the brink of recession.

Whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times. Yet despite the stock market’s recent gains, we think many shares still trade at a discount to their true value.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. We believe these stocks could be a great fit for any well-diversified portfolio with the goal of building wealth in your 50’s.

Claim your free copy now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

piggy bank, searching with binoculars
Investing Articles

Outlook: in just 12 months the BP share price could turn £10,000 into…

Forecasters seem pretty optimistic about prospects for the BP share price, suggesting it could be in for a major rally.…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

Down 28%, is Nvidia stock a bargain – or a value trap?

Nvidia stock has crashed this year -- but it's still a star performer over the long term! So, is this…

Read more »

Investing Articles

£10k invested in Barclays shares at the start of 2025 is now worth…

Harvey Jones says Barclays shares were unlikely to continue 2024's blistering run, given all the uncertainty out there. Yet long-term…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

Here’s how a first-time investor could start buying shares with £3k

Is it possible to start buying shares with £3K? Yes it is -- and here our writer goes into some…

Read more »

ISA Individual Savings Account
Investing Articles

Thinking of starting a Stocks and Shares ISA this April? Avoid these 4 mistakes!

A Stocks and Shares ISA can be a way for an investor to try and build wealth over the long…

Read more »

ISA coins
Investing Articles

Here’s how to build a £100k ISA starting with £5k today

Increase an ISA's value 20-fold? It need not just be the stuff of dreams, according to this writer -- though…

Read more »

A senior man and his wife holding hands walking up a hill on a footpath looking away from the camera at the view. The fishing village of Polperro is behind them.
Investing Articles

6.9% yield! I just added this share to my SIPP

In a turbulent stock market, our writer has been hunting for bargains to add to his SIPP. After a 31%…

Read more »

piggy bank, searching with binoculars
Investing Articles

With Rolls-Royce shares moving up again, is a £10 price target back on the horizon?

Rolls-Royce shares wobbled when President Trump dropped his tariff bombshell on us. But three weeks is a short time in…

Read more »